New postpartum depression drug gets almost $16,000 price tag, raising questions about access
- A newly approved medication to treat postpartum depression called Zurzuvae will be available in December at a cost of $15,900 per 14-day course, raising concerns about affordability and accessibility for patients.
- Sage Therapeutics and Biogen, the drugmakers, aim to provide financial assistance and coverage plans to ensure broad and equitable access for women prescribed Zurzuvae. However, some experts worry that the high cost may exacerbate healthcare disparities, as therapy is often sufficient for treatment.
- Postpartum depression, affecting 1 in 8 individuals who have babies, can have negative effects on maternal-infant bonding, family dynamics, and increase the risk of physical health issues. The approval of Zurzuvae offers an alternative to selective serotonin receptor inhibitors with potential faster improvements in depressive symptoms.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left2Leaning Right0Center27Last UpdatedBias Distribution93% Center
Bias Distribution
- 93% of the sources are Center
93% Center
C 93%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
